A strategy based on nucleotide specificity leads to a subfamily-selective and cell-active inhibitor of N6-methyladenosine demethylase FTO
A strategy based on nucleotide specificity leads to a subfamily-selective and cell-active inhibitor of $N^6$-methyladenosine demethylase FTO†


The AlkB family of nucleic acid demethylases are of intense biological and medical interest because of their roles in nucleic acid repair and epigenetic modification. However, their functional and molecular mechanisms are unclear, hence, there is strong interest in developing selective inhibitors for them. Here we report the identification of key residues within the nucleotide-binding sites of the AlkB subfamilies that likely determine their substrate specificity. We further provide proof of principle that a strategy exploiting these inherent structural differences can enable selective and potent inhibition of the AlkB subfamilies. This is demonstrated by the first report of a subfamily-selective and cell-active FTO inhibitor. The distinct selectivity of FTO against other AlkB subfamilies and 2OG oxygenases shall be of considerable interest with regards to its potential use as a functional probe. The strategy outlined here is likely applicable to other AlkB subfamilies, and, more widely, to other 2OG oxygenases.

Introduction

$N$-Methylation of DNA/RNA modifications can be found in the genomes of diverse organisms, including both prokaryotes and eukaryotes, and is of significant biological and clinical interest. There are at least 100 different modifications that are identified in cellular DNA and RNA. Some of these modifications, such as $N^4$-methyladenine (m1A) and $N^3$-methylcytosine (m3C) are damaging lesions which can lead to mutations, others are enzyme catalyzed, and have critical roles in cell biology; $N^2$-methylcytosine (m5C) and $N^6$-methyladenosine (m6A), in particular, are two of several epigenetic mechanisms for the regulation of gene expression (Fig. 1a). $N$-Methylation of nucleic acid can be directly reversed by the AlkB family of enzymes, of which the *Escherichia coli* AlkB is the first to be identified. Nine human homologues, ALKBH1-8 and FTO (fat mass and obesity-associated protein), have since been reported, many of these enzymes share common structural and mechanistic features with AlkB. Most of them employ ferrous iron as co-factor, and 2-oxoglutarate (2OG) as co-substrate to bring about oxidative-demethylation of $N$-methylated DNA/RNA substrates. This is achieved by oxidizing the $N$-methyl group to a hydroxymethyl group, which is coupled to the conversion of 2OG and O$_2$ to succinate and CO$_2$, respectively. The hydroxy-methyl intermediate then fragments spontaneously to give formaldehyde and the unmodified base (Fig. 1b).

The AlkB subfamilies demonstrate notable differences in their ‘substrate specificity’ and ‘nucleotide specificity’ (Fig. 1a). With respect to ‘substrate specificity’, some homologues, such as ALKBH2 showed strong preference for double-stranded DNA/RNA, whereas others, such as FTO and ALKBH3, are specific for single-stranded DNA/RNA. There are also distinct differences in ‘nucleotide specificity’, where methylation on a particular nucleotide is preferentially removed; ALKBH5, for instance, selectively demethylates m6A, while AlkB is able to accept a diverse range of methylated nucleotides. The factors determining their substrate specificity remain to be elucidated, although it is beginning to emerge that this can be, at least in part, due to structural differences in the catalytic domain and the nucleotide-recognition lid domain, or a result of the presence of adjacent structural elements.

Several AlkB enzymes are currently being targeted for the treatment of a range of human diseases. For instance, there is evidence that ALKBH2 and ALKBH3 both function as DNA/RNA repair enzymes *in vivo*. ALKBH3 (or prostate cancer antigen...
(PCA)-1), in particular, is highly expressed in prostate cancer cells and is an attractive therapeutic target for prostate cancer.\textsuperscript{18} Recently, ALKBH5 is reported to be involved in spermatogenesis,\textsuperscript{11} while the FTO gene is found to be strongly linked to obesity in genome wide association studies.\textsuperscript{19–21} FTO provides the strongest link to the common form of obesity, to date. However, despite the physiological connections with these enzymes, their exact molecular mechanisms remain unclear. The biological functions of the remaining human AlkB homologues are also largely unknown. With the exception of ALKBH4 and ALKBH8, which are known to catalyze the demethylation of actin K84me1, and the hydroxylation at the wobble position of tRNA, respectively, the catalytic activity of ALKBH6 and ALKBH7 remains to be clarified.\textsuperscript{22,23}

Hence, there is strong interest in developing selective and cell-active small molecule probes of AlkB subfamilies for structural, mechanistic and functional studies, with a longer term view of validating their therapeutic potential. Although there have been few reports of inhibitors of AlkB enzymes, most, if not all, have limited or undetermined selectivity.\textsuperscript{24–28} To date, there is no report of compound that is selective for a specific AlkB subfamily member. In addition, most reported inhibitors bind to the 2OG-binding site; to our knowledge, the nucleotide-binding site has not been rationally explored for inhibition.

Here, we report the use of a combined approach employing crystallographic studies, molecular modelling, fluorescence-based thermal shift analyses and enzyme assays, which led to the identification of significant differences within the nucleotide-binding domains that likely regulate the nucleotide specificity of the AlkB subfamilies. We further provide proof of principle that a strategy exploiting these inherent structural differences can enable selective and potent inhibition of the AlkB subfamily, as demonstrated by the first discovery of a selective and cell-active FTO inhibitor 12. Compound 12 not only demonstrates selectivity for FTO over other AlkB subfamilies (including ALKBH5 which, like FTO, accepts m6A substrate), it also discriminates against several other 2OG oxygenases. Such selectivity is rarely achieved for any enzyme family, and shall be of considerable interest with respect to its potential use as a functional probe; especially in dissecting the N6-methyladenosine modulating roles of FTO and ALKBH5 to facilitate the study of N6-methyladenosine dynamics in regulating cellular processes. The strategy outlined here is likely

![Fig. 1](image-url) The AlkB subfamilies and their (a) nucleotide specificity. (○ good activity; ● weak activity; □ no detectable activity). (b) Oxidative-demethylation reactions catalysed by AlkB enzymes. (c) $T_m$ shift studies with m3T and m6A substrates. The sequence for m6A-oligonucleotides is based on the consensus sites for m6A in human.\textsuperscript{3}
applicable to other AlkB subfamilies, and, more widely, to other 2OG oxygenases. Hence, it should enable the development of functional probes or therapeutic leads for these biologically and clinically important enzymes.

Results and discussion

Substrate selectivity of the AlkB subfamilies

To understand and to clarify the demethylase activity of the AlkB subfamilies, we first analyse the catalytic activities of all members of the AlkB family. In line with recent reports, our results reveal that, among the AlkB enzymes investigated, only FTO, AlkB, ALKBH1-3 and ALKBH5 are able to accept N-methylated DNA/RNA substrates (Fig. 1a and b). Further analysis of their nucleotide specificities reveals that FTO is the only subfamily member that is capable of removing N-methyl group(s) from DNA substrates (Fig. 1a and b). Moreover, the AlkB subfamilies probably only weakly bind to their substrates for FTO. Thus, it is reasonable to speculate that the polynucleotide backbone of the DNA/RNA substrate is likely not crucial for the binding of a methylated nucleotide. More-over, the AlkB subfamilies probably only weakly bind to their substrates for FTO.

Consistent with this observation, analysis of the binding affinities of m3T to AlkB subfamilies by differential scanning fluorimetry (DSF, an assay which indirectly measures the effect of ligands on protein stability) showed a particularly large Tm (melting temperature) shift for FTO (Tm shift = 12.1 °C), and no significant Tm shift for all other AlkB enzymes analyzed, indicating a selectivity of m3T for FTO (Fig. 1c). However, unexpectedly, the observed selectivity does not appear to extend to oligonucleotides that contain an m3T modification. In our Tm shift analyses, both the 5-mer and 15-mer m3T-containing ssDNAs, i.e. 5′-GG(m3T)CT3′ and 5′-ATTGGG(m3T)CTCGACG-3′, gave only modest Tm shifts which are similar to those obtained for their unmethylated counterparts (Fig. 1c). Notably, both m3T-oligonucleotides are substrates for FTO. Thus, it is reasonable to speculate that the polynucleotide backbone of the DNA/RNA substrate is likely not crucial for the binding of a methylated nucleotide. Moreover, the AlkB subfamilies probably only weakly bind to their DNA/RNA substrates. This hypothesis is supported by the large Tm shift observed for ALKBH5 with m6A (Tm shift = 9.3 °C), but not with the m6A-containing ssRNAs, 5-mer 5′-GG(m6A)CU-3′ and 15-mer 5′-ATTGGG(m6A)UGGCAGC-3′ (Fig. 1c). Both oligonucleotide sequences are based on the consensus sites for m6A in humans and are readily demethylated by ALKBH5.

Notably, m6A did not produce a significant Tm shift for FTO or AlkB (as observed with ALKBH5), even though both enzymes also accept m6A substrates (Fig. 1c). This implies that there are likely structural elements in ALKBH5 which select strongly for m6A, in line with its exclusivity for m6A substrates. However ALKBH5 likely binds to m6A with a ‘non-productive’ conformation, as ALKBH5 does not demethylate m6A nucleotide. Interestingly, all of the oligonucleotides tested (which are single-stranded DNA or RNA) gave significantly lower Tm shifts for ALKBH2 compared to other AlkB enzymes; this likely reflects ALKBH2’s strong preference for dsDNA/RNA over ssRNA/DNA.

Structural differences in the nucleotide-binding site of AlkB subfamilies

The combined results from nucleotide substrate profiling and Tm shift analyses suggest that there are likely structural features within the nucleotide-binding site of AlkB subfamilies (a deep, predominantly hydrophobic pocket in which the methylated nucleotide binds) that promote recognition and binding of a specific nucleotide (Fig. 2a). A crystal structure of FTO in complex with m3T and N-oxalylglycine (NOG, a catalytically inert amide analogue of 2OG) has been reported (PDB ID 3LFM). Structural analysis reveals that the 2OG-binding site is in close proximity to the nucleotide-binding site, and the recognition of m3T by FTO is achieved via interactions with six key residues within the nucleotide-binding site (Fig. 2a and b). In particular, the nucleobase ring of m3T participates in π–π interactions with the side chains of two highly conserved residues, Tyr108 and His231, while the deoxyribose ring of m3T is involved in hydrophobic interactions with the side chains of Leu109 and Val228. m3T is further stabilised by hydrogen-bonding interactions between O3′-m3T and Arg96 (side chain, 3.1 Å), and between O3′-m3T and Glu234 (amide backbone, 2.9 Å).

To understand the structural basis for the apparent lack of affinity of m3T for other AlkB demethylases, we superimposed the crystal structures of FTO-m3T-NOG complex (PDB ID 3LFM) with that of AlkB (PDB ID 3I3M), ALKBH2 (PDB ID 3BUC), ALKBH3 (PDB ID 2IUIW), and ALKBH5 (PDB ID 4N4J); several of these structures are in complex with their methylated oligonucleotide substrates and/or NOG. Inspection of the residues lining the nucleotide-binding sites of AlkB and ALKBH2 revealed that most of the residues that are important for m3T recognition by FTO are either conserved, or substituted by structurally equivalent residues (Fig. S1a and S1b†). The exception is Arg96, which is substituted by Met61AlkB and Gln112ALKBH2, leading to the loss of interactions with O3′-m3T and Arg96 (side chain, 3.1 Å), and between O3′-m3T and Glu234 (amide backbone, 2.9 Å).

Strategy for the development of subfamily-selective FTO inhibitor

Overall, our crystallographic analysis revealed significant differences in the nucleotide-binding sites of the AlkB subfamilies, which may, at least partially, rationalise their nucleotide selectivity (Fig. 1b). Importantly, these inherent structural differences may be exploited to achieve selective inhibition of AlkB subfamilies. To date, there is no report of a selective inhibitor of the AlkB enzymes, let alone a subfamily-selective inhibitor. Moreover, with the exception of FTO inhibitor, rhein, all reported inhibitors bind to the 2OG-binding
The nucleotide-binding site has not been explored, at least rationally, for inhibition. We reasoned that a strategy that simultaneously occupies both the 2OG- and nucleotide-binding sites may enable both potency and selectivity (Fig. 2a).

In the design of a ‘two-component’ inhibitor that is selective for FTO, we linked a ‘2OG-binding component’, namely succinate hydrazide 1, fumarate hydrazide 2 or maleate hydrazide 3, which are predicted to chelate to the active site iron in FTO with an appropriate side chain (‘m3T-binding component’) for extension into the nucleotide-binding site (Scheme 1 and Table S1†). Modelling studies based on the structures of FTO in complex with m3T and NOG identified various pyridyl side chains as having the correct relative distance and geometry for mimicking m3T interactions in the nucleotide-binding site; this gives rise to a series of acylhydrazine compounds 1–20 (Table S1†). The synthesis of the succinate and maleate derivatives involves the acylation of succinate or maleate anhydride with the desired monoacylhydrazines, while the synthesis of the fumarate derivatives uses hydrazide coupling as a key step; this involves the nucleophilic substitution of ethyl pentafluorophenyl fumarate with appropriate monoacylhydrazines, followed by basic hydrolysis to obtain the corresponding acids (Scheme 1, see ESI†).

Preliminary evaluation of compounds 1–20 for activities against FTO was achieved using both a DSF-binding assay and a HPLC-based demethylase assay which employs m3T as substrate (Fig. S2†). We identified several compounds with IC50 values in the low micromolar range (i.e. compounds 8, 12, 14, and 16–20; Table S1†); the Tm shift results supported the IC50 values, where compounds that were more potent gave higher Tm shifts than those that were less potent. In general, fumarate derivatives are better FTO inhibitors than the corresponding succinate and maleate derivatives. The most potent inhibitor identified is compound 12 (IC50 = 0.81 μM, Tm shift = 11.2 °C),

The nucleotide-binding site has not been explored, at least rationally, for inhibition. We reasoned that a strategy that simultaneously occupies both the 2OG- and nucleotide-binding sites may enable both potency and selectivity (Fig. 2a).

In the design of a ‘two-component’ inhibitor that is selective for FTO, we linked a ‘2OG-binding component’, namely succinate hydrazide 1, fumarate hydrazide 2 or maleate hydrazide 3, which are predicted to chelate to the active site iron in FTO with an appropriate side chain (‘m3T-binding component’) for extension into the nucleotide-binding site (Scheme 1 and Table S1†). Modelling studies based on the structures of FTO in complex with m3T and NOG identified various pyridyl side chains as having the correct relative distance and geometry for mimicking m3T interactions in the nucleotide-binding site; this gives rise to a series of acylhydrazine compounds 1–20 (Table S1†). The synthesis of the succinate and maleate derivatives involves the acylation of succinate or maleate anhydride with the desired monoacylhydrazines, while the synthesis of the fumarate derivatives uses hydrazide coupling as a key step; this involves the nucleophilic substitution of ethyl pentafluorophenyl fumarate with appropriate monoacylhydrazines, followed by basic hydrolysis to obtain the corresponding acids (Scheme 1, see ESI†).

Preliminary evaluation of compounds 1–20 for activities against FTO was achieved using both a DSF-binding assay and a HPLC-based demethylase assay which employs m3T as substrate (Fig. S2†). We identified several compounds with IC50 values in the low micromolar range (i.e. compounds 8, 12, 14, and 16–20; Table S1†); the Tm shift results supported the IC50 values, where compounds that were more potent gave higher Tm shifts than those that were less potent. In general, fumarate derivatives are better FTO inhibitors than the corresponding succinate and maleate derivatives. The most potent inhibitor identified is compound 12 (IC50 = 0.81 μM, Tm shift = 11.2 °C),

The nucleotide-binding site has not been explored, at least rationally, for inhibition. We reasoned that a strategy that simultaneously occupies both the 2OG- and nucleotide-binding sites may enable both potency and selectivity (Fig. 2a).

In the design of a ‘two-component’ inhibitor that is selective for FTO, we linked a ‘2OG-binding component’, namely succinate hydrazide 1, fumarate hydrazide 2 or maleate hydrazide 3, which are predicted to chelate to the active site iron in FTO with an appropriate side chain (‘m3T-binding component’) for extension into the nucleotide-binding site (Scheme 1 and Table S1†). Modelling studies based on the structures of FTO in complex with m3T and NOG identified various pyridyl side chains as having the correct relative distance and geometry for mimicking m3T interactions in the nucleotide-binding site; this gives rise to a series of acylhydrazine compounds 1–20 (Table S1†). The synthesis of the succinate and maleate derivatives involves the acylation of succinate or maleate anhydride with the desired monoacylhydrazines, while the synthesis of the fumarate derivatives uses hydrazide coupling as a key step; this involves the nucleophilic substitution of ethyl pentafluorophenyl fumarate with appropriate monoacylhydrazines, followed by basic hydrolysis to obtain the corresponding acids (Scheme 1, see ESI†).

Preliminary evaluation of compounds 1–20 for activities against FTO was achieved using both a DSF-binding assay and a HPLC-based demethylase assay which employs m3T as substrate (Fig. S2†). We identified several compounds with IC50 values in the low micromolar range (i.e. compounds 8, 12, 14, and 16–20; Table S1†); the Tm shift results supported the IC50 values, where compounds that were more potent gave higher Tm shifts than those that were less potent. In general, fumarate derivatives are better FTO inhibitors than the corresponding succinate and maleate derivatives. The most potent inhibitor identified is compound 12 (IC50 = 0.81 μM, Tm shift = 11.2 °C),

The nucleotide-binding site has not been explored, at least rationally, for inhibition. We reasoned that a strategy that simultaneously occupies both the 2OG- and nucleotide-binding sites may enable both potency and selectivity (Fig. 2a).

In the design of a ‘two-component’ inhibitor that is selective for FTO, we linked a ‘2OG-binding component’, namely succinate hydrazide 1, fumarate hydrazide 2 or maleate hydrazide 3, which are predicted to chelate to the active site iron in FTO with an appropriate side chain (‘m3T-binding component’) for extension into the nucleotide-binding site (Scheme 1 and Table S1†). Modelling studies based on the structures of FTO in complex with m3T and NOG identified various pyridyl side chains as having the correct relative distance and geometry for mimicking m3T interactions in the nucleotide-binding site; this gives rise to a series of acylhydrazine compounds 1–20 (Table S1†). The synthesis of the succinate and maleate derivatives involves the acylation of succinate or maleate anhydride with the desired monoacylhydrazines, while the synthesis of the fumarate derivatives uses hydrazide coupling as a key step; this involves the nucleophilic substitution of ethyl pentafluorophenyl fumarate with appropriate monoacylhydrazines, followed by basic hydrolysis to obtain the corresponding acids (Scheme 1, see ESI†).

Preliminary evaluation of compounds 1–20 for activities against FTO was achieved using both a DSF-binding assay and a HPLC-based demethylase assay which employs m3T as substrate (Fig. S2†). We identified several compounds with IC50 values in the low micromolar range (i.e. compounds 8, 12, 14, and 16–20; Table S1†); the Tm shift results supported the IC50 values, where compounds that were more potent gave higher Tm shifts than those that were less potent. In general, fumarate derivatives are better FTO inhibitors than the corresponding succinate and maleate derivatives. The most potent inhibitor identified is compound 12 (IC50 = 0.81 μM, Tm shift = 11.2 °C),
which is 45-fold more active than the ‘generic’ inhibitor NOG (IC\textsubscript{50} = 36.5 \mu M, T\textsubscript{m} shift = 4.1 °C). To verify the HPLC-based assay results, the activity of 12 against FTO was further evaluated using a MALDI-based assay. In this assay, an m6A-ssDNA was used as substrate instead of m3T, and a comparable IC\textsubscript{50} value of 1.1 \mu M was obtained (Fig. S3\textsuperscript{†}).

Importantly, profiling studies revealed distinct selectivity of 12 for FTO, with significantly reduced inhibition and T\textsubscript{m} shifts against ALKB (IC\textsubscript{50} = 33.5 \mu M, T\textsubscript{m} shift = 4.5 °C) and ALKBH2 (IC\textsubscript{50} = 25.9 \mu M, T\textsubscript{m} shift = 4.9 °C), and little or no inhibition or T\textsubscript{m} shift against ALKBH3 (IC\textsubscript{50} = 66.2 \mu M, T\text{m shift} = 3.2 °C) and ALKBH5 (IC\textsubscript{50} = 108.1 \mu M, T\text{m shift} = 2.7 °C) (Fig. 3a and b). The selectivity profile of 12 is notable because it is highly consistent with the specificity of m3T for the AlkB subfamilies. This specificity is likely derived from the 4-benzylpyridyl side chain of 12 i.e. the ‘m3T-binding component’, as fumarate hydrazide 2 showed poor activity for FTO (IC\textsubscript{50} > 100 \mu M, Table S1\textsuperscript{†}). In addition, structurally related succinate hydrazide 1, maleate hydrazide 3 and daminozide (a plant growth regulator that is known to inhibit KDM2/7 histone demethylases)\textsuperscript{33} also showed poor activities against FTO (IC\textsubscript{50} > 100 \mu M, Table S1). The lack of inhibition of 12 against ALKBH5 is also remarkable because ALKBH5, like FTO, accepts m6A in RNA as major physiological substrates.\textsuperscript{22} In the FTO and ALKBH5 assays described above, we have used m3T and/or m6A-ssDNA as substrates. To investigate if the selectivity of 12 extends to the demethylation of m6A on RNA by FTO and ALKBH5, we further evaluated the activity of 12 against both enzymes using short m6A-containing ssRNA as substrates. In both assays, comparable IC\textsubscript{50} values of 0.6 \mu M and 96.5 \mu M were obtained for FTO and ALKBH5, respectively (Fig. 3a and S4\textsuperscript{†}). This represents >100-fold selectivity for FTO over ALKBH5. The ability of 12 to discriminate against ALKBH5 shall make it a potential functional probe in dissecting the respective roles of FTO and ALKBH5 in m6A-mediated epigenetic processes.

**Kinetics, crystallographic analyses and mode of inhibition**

A detailed kinetic study of FTO inhibition by 12 was then performed using a HPLC-based method. The analyses reveal that 12 demonstrates a mixed mode of inhibition with respect to m3T (K\textsubscript{i}\text{app} = 2.1 \mu M, α = 2.0), indicating that 12 binds to both FTO and FTO-m3T complex, possibly with preference for binding to free FTO (Fig. 3c). However 12 is predominantly a competitive inhibitor with respect to co-substrate 2OG (K\textsubscript{i}\text{app} = 1.4 \mu M) (Fig. 3d).

To understand the structural features that underlie the selectivity of 12, we determined a crystal structure of FTO in complex with 12 (PDB ID 4CXW, Fig. 4a). As with other FTO structures, the nickel active site (substituting for iron) is coordinated by the side chains of three highly conserved residues, His231 (2.3 Å), Asp233 (2.4 Å), His307 (2.4 Å), and a putative water molecule located trans (2.7 Å) to His231. The 2OG-
Fig. 4 Views from structures of FTO (white sticks) bound to (a) 12 (orange stick, PDB ID 4CXW), (b) 16 (purple sticks, PDB ID 4CXX), and (c) 21 (green stick, PDB ID 4CXY). The unbiased difference Fourier electron density maps ($F_o - F_c$), displayed as grey mesh, are shown to the right.

Ni(II) (magenta sphere, substituting for Fe(II)) is coordinated by the side chains of three highly conserved residues, His231 (2.3 Å), Asp233 (2.4 Å), His307 (2.4 Å), and a putative water molecule located trans (2.7 Å) to His231. 12 chelates to nickel in a bidentate manner, with the C-4 carbonyl oxygen of 12 (2.1 Å) trans to Asp233 and the hydrazine nitrogen of 12 (2.1 Å) trans to His307. The C-1 carboxylate oxygens of 12 are positioned to form salt bridges to Arg316 (3.0 Å and 3.1 Å), and to hydrogen-bonds with the hydroxyl group of Tyr295 (2.7 Å), and to the side chain oxygen of Ser318 (2.9 Å). 16 binds in an analogous manner as 12. 21 simultaneously binds to the second Ni(II) via its hydrazine nitrogen (2.9 Å) and its pyridyl carbonyl oxygen (3.6 Å); this nickel is further stabilised through coordination to the side chains of Asn205 (3.2 Å, 3.3 Å), Thr320 (3.2 Å) and Arg322 (3.2 Å).
binding component’ of 12 i.e. fumurate hydrazide 2 resides in the 2OG-binding site, as predicted. It coordinates to nickel through the acylhydrazine group of 12 in a bidentate manner, with the C-4 carbonyl oxygen of 12 (2.1 Å) trans to Asp233 and the hydrazine nitrogen of 12 (2.1 Å) trans to His307. The C-1 carbonylate oxygens of 12 are positioned to form salt bridges to Arg316 (3.0 Å and 3.1 Å), and to form hydrogen-bonds with the hydroxyl group of Tyr293 (2.7 Å), and to the side chain oxygen of Ser318 (2.9 Å).

Notably, an overlay of this crystal structure with that of FTO-m3T-NOG complex (PDB ID 3LPM)41 reveals that the fumurate hydrazide of 12 is in close alignment with NOG (Fig. 2c). As expected, the ‘m3T-binding component’ of 12 i.e. the 4-benzyl pyridine side chain inserts into the nucleotide-binding site, and superimposes almost perfectly with m3T. This enables 12 to make nearly identical interactions as m3T with FTO (Fig. 2c). Hence, as with the nucleobase ring of m3T, the pyridyl ring of 12 is sandwiched between the side chains of Tyr108 and His231 to enable similar π–π interactions. In addition, the pyridyl nitrogen is situated in the same relative position as O4-m3T, and forms analogous hydrogen-bonding interactions with the amide backbone of Glu234 (2.9 Å). Although no corresponding interaction with Arg96 is observed for 12, this is presumably compensated for by an additional hydrogen-bond between the pyridyl carbonyl oxygen of 12 and the side chain of Arg322 (2.8 Å, Fig. 4a). The 4-benzyl substituent of 12 occupies equivalent position as the sugar ring of m3T, and participates in similar hydrophobic interactions with Leu109 and Val228. There is no significant difference in the overall conformations of all the residues in both crystal structures (RMSD of all atoms = 0.5 Å). Similar mode of binding is also observed for 16 (an analogue of 12, Table S1†) as determined by a crystal structure of FTO in complex with 16 (PDB ID 4CXX, Fig. 4b).

Modelling study reveals that most of the interactions between 12 and the 2OG-binding site of FTO are conserved in AlkB and ALKBH2,3,5 (Fig. 5). There are, however, significant differences in the interactions of 12 with the nucleotide-binding sites of these demethylases. In particular, the corresponding interaction between the pyridyl nitrogen of 12 and Glu234rFTO is either abolished or significantly weakened in all other subfamilies investigated; apparently, the equivalent residues i.e. Asp135AlkB, Asp174ALKBH2, Asp194ALKBH3 and Pro207ALKBH5 are too distant to make significant contact with the pyridyl nitrogen. In addition, unlike Tyr108rFTO, Trp69AlkB and Phe124ALKBH2, which are involved in π–π interactions with the pyridyl ring of 12, the corresponding residues in ALKBH3 (Tyr143) and ALKBH5 (Tyr139) are unable to achieve the correct alignment for similar stacking interactions. These factors may, at least in part, rationalise the selectivity of 12 for FTO over other AlkB subfamilies.

The lack of activities of 12 for AlkB is interesting because it has been suggested that the substrate binding ‘lid’ of AlkB is conformationally flexible, and this likely enables AlkB to accept a diverse range of alkylated nucleotide substrates.6,8 Hence, it is conceivable that AlkB undergoes a similar conformational change at its nucleotide-binding site to accommodate the binding of 12. However, superimposition of a crystal structure of the AlkB-dsDNA complex (PDB ID: 3I3Q)43 with the unliganded AlkB proteins (PDB ID: 4NID)42 reveals no significant change in the conformation of residues lining the nucleotide-binding site of AlkB (RMSD of all atoms = 0.2 Å, Fig. S5†). Consistent with studies by others,8,46 our data indicate that the flexibility of AlkB is largely localised to the Asp135-Pro142 loop, where movement is observed with Asp135 (Fig. S5a†). Modelling studies with FTO and ALKBH5 also reveal minimal conformational change in the nucleotide-binding sites of both enzymes on binding with their respective substrates (RMSD of all atoms = 0.6 Å (FTO), 0.4 Å (ALKBH2), and 0.3 Å (ALKBH5), Fig. S5†); we were unable to obtain an accurate model of ALKBH3. In line with previous studies, the only notable conformational change observed is the ‘flipping’ of the side chain of Tyr141ALKBH5 in the presence of nucleotide substrate.46 Overall, our available results imply that the nucleotide-binding sites of AlkB, FTO, and ALKBH2,5 likely remain unchanged upon interaction with 12.

To probe the roles of the respective residues within the nucleotide-binding site for selective inhibition, we further synthesised compounds 21–23 using the methods described in Scheme 1 (Fig. 3a; see the ESI†). Activity studies suggest that the residues involved in sugar ring interactions are important for potency for all AlkB subfamilies, as 21, which lacks the participating 4-benzyl group of 12, has greatly reduced activity against all subfamilies tested (IC50 (FTO) = 11.8 μM, IC50s (ALKBH2,3,5) > 100 μM). These interactions, however, are likely not crucial for selectivity, as 21 retains >10-fold selectivity for FTO. In contrast, the interactions with Glu234 appear to be critical, as demonstrated by the dramatic loss of potency and selectivity of the 2-pyridyl compounds, 22 (IC50 = 86.8 μM) and 23 (IC50 = 109.4 μM), compared with their 3-pyridyl parents, 14 (IC50 = 1.02 μM) and 21 (IC50 = 11.8 μM), respectively (we were unable to synthesise the 2-pyridyl analogue for 12). By inference from a crystal structure of FTO in complex with 21 (PDB ID 4CXY, Fig. 4c), this subtle switch in the pyridyl nitrogen position prevents 22 and 23 from forming hydrogen-bonds with Glu234. Hence, the results indicate that Glu234 is likely a key determinant for substrate specificity for FTO; this is consistent with a previous report where site-directed mutagenesis of Glu234 abolished FTO demethylase activity on m3T.13

In general, acrylhydrazine compounds are expected to chelate to metal in solution.37 Thus, it is possible that 12 inhibits FTO predominantly through a depletion of iron in solution, or from sequestration of iron at the active site of FTO. However, we observed that the IC50s for 12 and most of its analogues (i.e. 14, 16–20) are 25-fold to 100-fold less than the concentration of iron (100 μM) used in the biochemical assays. There was also no significant change in the IC50 of 12 when the iron concentration was increased from 100 μM to 500 μM (results not shown). These results indicate that the inhibitory activity of 12 is not dependent on the concentration of iron. It also provides evidence that the mode of inhibition of 12 is, at least in part, a result of specific interactions in the catalytic domain of FTO, and not predominantly due to non-specific chelation to iron.

Interestingly, crystallographic analysis of the FTO in complex with 21 (PDB ID 4CXY) showed distinct electron density within the 2OG-binding site, which is consistent with the presence of a
second nickel that is not normally present (Fig. 4c). 21 apparently induces binding to a second nickel via its hydrazine nitrogen (2.9 Å) and its pyridyl carbonyl oxygen (3.6 Å); this nickel is further stabilised by chelation to the side chains of Asn205 (3.2 Å, 3.3 Å), Thr320 (3.2 Å) and Arg322 (3.2 Å). However, the observed two-metal binding is likely dependent on enzyme, as previous mass spectrometric and docking studies of 21 with PHD2 (prolyl hydroxylase domain-containing protein 2) did not indicate two-metal binding. Moreover, not all acylhydrazines can simultaneously bind to a second metal; in the crystal structures of the FTO-12 and FTO-16 complexes, the corresponding position for the second nickel is occupied by a water molecule under our crystallographic conditions (Fig. 4a and b).

**Selectivity profiling and cellular activity**

To investigate the selectivity of 12 against other Fe(II)- and 2OG-dependent oxygenases, 12 was tested for inhibition against two clinically important human 2OG oxygenases, PHD2 and JMJD2A (an oxygen sensing enzyme, which is central to hypoxic response) and JMJD2A (jmjC histone lysine demethylase, targeted for the treatment of cancer). 12 showed IC_{50} > 100 μM and >300 μM for PHD2 and JMJD2A, respectively, thus demonstrating 100–300 fold selectivity towards FTO. Notably, 21 is a known potent inhibitor of PHD2 (IC_{50} (PHD2) = 82 nM). The lack of inhibition of 12 for PHD2 and for JMJD2A further demonstrates that the proposed strategy based on nucleotide specificity can enable compounds with the desired selectivity profile. Recently, nucleic acid demethylases from other family have been identified, such as the ten-eleven translocation (TET) enzymes, which are known to regulate the level of 5-methylcytosine (m5C) in CpG regions. Further characterisation of 12 against DNA/RNA demethylases from a ‘non-AlkB’ family will be important in defining its utility as a chemical probe.

Finally, to explore the cellular efficacy of 12, we tested the ethyl ester derivative of 12 i.e. 25 on HeLa cells. Preliminary study on the intracellular hydrolysis of 25 reveals that about 35% of 25 that entered the cells is hydrolysed to 12 (for the method, see the ESI†). Notably, despite potential stability and
Studies on the selectivity of ALKBH5. To date, FTO and AlkBH5 are the only two enzymes known to demethylate m6A substrate in human. Notably, m6A is one of the most abundant post-translational modifications that are involved in the recognition and/or selection of methylated substrates, some of these domains are not present in all AlkB subfamilies; to date, only FTO and AlkBH5 were reported to possess the L1 loop. Consistent with recent study by others, we demonstrated that the substrate specificity of the AlkB enzymes can arise, at least in part, from structural differences within their nucleotide-binding sites. Notably, Glu234FTO is likely a key residue that determines the affinity and specificity of FTO for its substrates.

We further provide proof of principle that a strategy exploiting these inherent structural differences in the nucleotide-binding sites of AlkB subfamilies can enable selective and potent inhibition of the AlkB enzymes. Through this approach, we identified compound 12 as a potent and subtype-selective inhibitor of the medically important FTO. Crystallographic analysis reveals that 12 occupies a previously unexplored region of the substrate binding site. Selectivity profiling demonstrates that 12 not only exhibits 30-fold to 130-fold selectivity for FTO over other AlkB subfamilies, it also discriminates against other human 2OG oxygenases, as shown by a lack of inhibition for PHD2 and JMJD2A. The cell-based assay further indicates that 25, the ethyl ester derivative of 12, is able to inhibit m6A demethylase activity in cells. To our knowledge, this is the first time that an inhibitor which is selective for a particular AlkB subfamily member is reported. Such selectivity profile shall be of widespread interest with regard to its potential use as a functional probe and, possibly, therapeutic lead.

Importantly, 12 showed clear selectivity for FTO over AlkBH5. To date, FTO and AlkBH5 are the only two enzymes known to demethylate m6A substrate in human. Notably, m6A is one of the most abundant post-translational modifications in eukaryotes RNA, and is widely considered to be a novel epigenetic mark. There is increasing evidence that the dynamic m6A modification is central to the regulation of a wide range of cellular processes. 12 should, therefore, greatly facilitate the study of the respective roles of FTO and AlkBH5 in m6A-mediated epigenetic processes.

It is envisaged that the strategy outlined here is generally applicable to the selective inhibition of other AlkB subfamilies and, more widely, to other 2OG oxygenases. A challenge will be to apply this strategy to the discovery of selective probes or therapeutic leads for every member of this biologically and clinically important class of enzymes.

Conflict of interest

The authors declare no competing financial interest.

Acknowledgements

We thank Dr Giles Yeo (University of Cambridge Metabolic Research Lab) for generously providing the FTO construct used in this study. This research was supported by the Singapore National Research Foundation under its CBGR-NIG scheme (BNIG12nov001) and administered by the Singapore Ministry of Health’s National Medical Research Council. It is also

Conclusions

Overall we report the combined crystallographic, molecular modelling, Tm shift, and biochemical studies on the determinants that regulate nucleotide specificity within the AlkB subfamilies. Although structural elements, such as the nucleotide-recognition lid domain and the L1 loop are likely involved in the recognition and/or selection of methylated substrates, some of these domains are not present in all AlkB subfamilies; to date, only FTO and AlkBH5 were reported to possess the L1 loop. Consistent with recent study by others, we demonstrated that the substrate specificity of the AlkB enzymes can arise, at least in part, from structural differences within their nucleotide-binding sites. Notably, Glu234FTO is likely a key residue that determines the affinity and specificity of FTO for its substrates.

We further provide proof of principle that a strategy exploiting these inherent structural differences in the nucleotide-binding sites of AlkB subfamilies can enable selective and potent inhibition of the AlkB enzymes. Through this approach, we identified compound 12 as a potent and subtype-selective inhibitor of the medically important FTO. Crystallographic analysis reveals that 12 occupies a previously unexplored region of the substrate binding site. Selectivity profiling demonstrates that 12 not only exhibits 30-fold to 130-fold selectivity for FTO over other AlkB subfamilies, it also discriminates against other human 2OG oxygenases, as shown by a lack of inhibition for PHD2 and JMJD2A. The cell-based assay further indicates that 25, the ethyl ester derivative of 12, is able to inhibit m6A demethylase activity in cells. To our knowledge, this is the first time that an inhibitor which is selective for a particular AlkB subfamily member is reported. Such selectivity profile shall be of widespread interest with regard to its potential use as a functional probe and, possibly, therapeutic lead.

Importantly, 12 showed clear selectivity for FTO over AlkBH5. To date, FTO and AlkBH5 are the only two enzymes known to demethylate m6A substrate in human. Notably, m6A is one of the most abundant post-translational modifications in eukaryotes RNA, and is widely considered to be a novel epigenetic mark. There is increasing evidence that the dynamic m6A modification is central to the regulation of a wide range of cellular processes. 12 should, therefore, greatly facilitate the study of the respective roles of FTO and AlkBH5 in m6A-mediated epigenetic processes.

It is envisaged that the strategy outlined here is generally applicable to the selective inhibition of other AlkB subfamilies and, more widely, to other 2OG oxygenases. A challenge will be to apply this strategy to the discovery of selective probes or therapeutic leads for every member of this biologically and clinically important class of enzymes.

Conflict of interest

The authors declare no competing financial interest.

Acknowledgements

We thank Dr Giles Yeo (University of Cambridge Metabolic Research Lab) for generously providing the FTO construct used in this study. This research was supported by the Singapore National Research Foundation under its CBGR-NIG scheme (BNIG12nov001) and administered by the Singapore Ministry of Health’s National Medical Research Council. It is also


